SELARL PHARMACIE SCHIR VINCENT : revenue, balance sheet and financial ratios

SELARL PHARMACIE SCHIR VINCENT is a French company founded 9 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in MEYLAN (38240), this company of category PME shows in 2021 a revenue of 2.2 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-25

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SELARL PHARMACIE SCHIR VINCENT (SIREN 830056115)
Indicator 2025 2024 2023 2022 2021 2020 2019 2018
Revenue N/C N/C N/C N/C 2 183 970 € 2 151 252 € 1 974 099 € 1 654 858 €
Net income 47 878 € 100 986 € 46 162 € 131 787 € 100 720 € 92 418 € 74 571 € 4 534 €
EBITDA N/C N/C N/C N/C 154 465 € 146 466 € 114 716 € 107 428 €
Net margin N/C N/C N/C N/C 4.6% 4.3% 3.8% 0.3%

Revenue and income statement

In 2025, SELARL PHARMACIE SCHIR VINCENT generates positive net income of 48 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2018-2025: 5 k€ -> 48 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

47 878 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 48%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 50%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

47.678%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

49.941%

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

42.9%

Solvency indicators evolution
SELARL PHARMACIE SCHIR VINCENT

Sector positioning

Debt ratio
47.68 2025
2023
2024
2025
Q1: 13.71
Med: 49.76
Q3: 129.07
Good -8 pts over 3 years

In 2025, the debt ratio of SELARL PHARMACIE SCHIR VI... (47.68) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
49.94% 2025
2023
2024
2025
Q1: 33.42%
Med: 53.71%
Q3: 72.08%
Average +8 pts over 3 years

In 2025, the financial autonomy of SELARL PHARMACIE SCHIR VI... (49.9%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 115.90. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

115.902

Liquidity indicators evolution
SELARL PHARMACIE SCHIR VINCENT

Sector positioning

Liquidity ratio
115.9 2025
2023
2024
2025
Q1: 131.03
Med: 182.29
Q3: 258.7
Watch

In 2025, the liquidity ratio of SELARL PHARMACIE SCHIR VI... (115.90) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
SELARL PHARMACIE SCHIR VINCENT

Positioning of SELARL PHARMACIE SCHIR VINCENT in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 277 transactions of similar company sales in 2025, the value of SELARL PHARMACIE SCHIR VINCENT is estimated at 760 547 € (range 516 111€ - 1 193 404€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
277 transactions
516k€ 760k€ 1193k€
760 547 € Range: 516 111€ - 1 193 404€
NAF 5 année 2025

Valuation method used

Net Income Multiple
47 878 € × 15.9x = 760 548 €
Range: 516 111€ - 1 193 404€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare SELARL PHARMACIE SCHIR VINCENT with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about SELARL PHARMACIE SCHIR VINCENT

What is the revenue of SELARL PHARMACIE SCHIR VINCENT ?

The revenue of SELARL PHARMACIE SCHIR VINCENT in 2021 is 2.2 M€.

Is SELARL PHARMACIE SCHIR VINCENT profitable?

Yes, SELARL PHARMACIE SCHIR VINCENT generated a net profit of 48 k€ in 2025.

Where is the headquarters of SELARL PHARMACIE SCHIR VINCENT ?

The headquarters of SELARL PHARMACIE SCHIR VINCENT is located in MEYLAN (38240), in the department Isere.

Where to find the tax return of SELARL PHARMACIE SCHIR VINCENT ?

The tax return of SELARL PHARMACIE SCHIR VINCENT is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SELARL PHARMACIE SCHIR VINCENT operate?

SELARL PHARMACIE SCHIR VINCENT operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.